The nation of Zimbabwe has turned down a substantial American healthcare agreement valued at 367 million US dollars (£272m) spanning five years due to Washington's demand for sensitive biological samples.
This rejection became public after a government memo from December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
An official representative later explained that the United States was demanding access to biological samples for research and profit while was unwilling to share the resulting advantages from any future treatments.
"We must now begin the difficult and regrettable process of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had furnished over $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for more negotiations to find a deal agreeable to all parties so the country's vital HIV treatment initiative can proceed.
Wider Background
This rejection comes after a similar situation in Kenya, where a high court blocked a similar health funding agreement following legal challenges were filed about the security of Kenyans' medical information.
Since returning to the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had managed assistance for the US government, but Trump argued its expenditure was "inefficient" and his government was pursuing direct bilateral agreements to enhance openness and accountability.
According to reports, 16 nations in Africa have so far signed these new agreements, constituting more than $18.3bn in committed funds.
Details of the Declined Deal
The money for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this partnership could have provided extraordinary advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently on antiretroviral therapy via American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"Zimbabwe was being asked to provide its biological resources and data over an extended period, with no corresponding guarantee of benefiting from any medical innovations – such as new medicines or tests – that might result from that provided information," his statement read.
"Put simply, our nation would provide the raw materials for scientific discovery without any assurance that the final treatments would be accessible to our citizens if a new disease outbreak emerge."
National Interest and Global Health
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were undermining structures already set up via the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to manage potential pandemics.
"This framework is designed to guarantee that when a nation provides its data, the benefits – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as opposition to America," he added.
"We welcome further dialogue with our American counterparts on how subsequent co-operation could be designed in a way that honours the sovereignty and dignity of each country."
Health Experts Reaction
A leading public health body stated it acknowledged the government's concerns, but suggested that negotiations must proceed given that a large portion of the nation's HIV programmes were funded by international support.
"If specific concerns exist, such as those involving data governance or implementation frameworks, these can often be addressed through detailed discussion and negotiated safeguards," it said.
The halted deal underscores the ongoing challenges between receiving much-needed international aid and protecting local interests in an ever more data-driven world.